Taken together, autophagy plays a cytoprotective role in afatinib therapy and the inhibition of autophagy shows an increased sensitivity of lung adenocarcinoma cells harboring activating EGFR mutations to afatinib. Here, EGFR is linked to lung adenocarcinoma.